A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Overview of attention for article published in Frontiers in Pediatrics, March 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 9,415 followers.

Open Access UCL Research: A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N https://t.co/jIJrvCqzdt

28 Nov 2023

Reply Repost Favourite

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177 Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N #HelsinkiHealth #tutkimus #tiede https://t.co/rjqHkltj55

04 Apr 2022

Reply Repost Favourite

RT @MarkGaze: #AimingForCure in #Neuroblastoma. A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOT…

10 Mar 2022

Reply Repost Favourite

#AimingForCure in #Neuroblastoma. A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma. LuDO-N is an innovative attempt to improve outcomes.

10 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.